vbi vaccines inc. (nasdaq: vbiv) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. vbi’s evlp vaccine platform allows for the design of enveloped (“e”) virus-like particle (“vlp”) vaccines that closely mimic the target virus. the company’s lead evlp asset is a prophylactic cytomegalovirus (cmv) vaccine; vbi has initiated work for gmp manufacturing of its cmv candidate for use in formal preclinical and phase i trials. the company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. vbi has completed proof of concept thermostability studies on a number of vaccine and biologic targets. vbi is headquartered in cambridge, ma with research facilities in ottawa, canada.
Company profile
Ticker
VBIV
Exchange
Website
CEO
Jeffrey R. Baxter
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LEVON RESOURCES LTD, LEVON RESOURCES LTD., SciVac Therapeutics Inc.
SEC CIK
Corporate docs
Subsidiaries
VBI Vaccines (Delaware) Inc. • SciVac Ltd. • Variation Biotechnologies (US), Inc. • Variation Biotechnologies Inc. • SciVac Hong Kong Limited ...
VBIV stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
16 Apr 24
8-K
VBI Vaccines Reports Full Year 2023 Financial Results
16 Apr 24
8-K
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11 Apr 24
424B5
Prospectus supplement for primary offering
11 Apr 24
8-K
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
3 Apr 24
8-K
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
2 Apr 24
NT 10-K
Notice of late annual filing
28 Mar 24
8-K
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
14 Feb 24
8-K
Entry into a Material Definitive Agreement
6 Feb 24
8-K
Entry into a Material Definitive Agreement
23 Jan 24
Latest ownership filings
SC 13D/A
PERCEPTIVE ADVISORS LLC
17 Apr 24
SC 13D/A
PERCEPTIVE ADVISORS LLC
20 Nov 23
4
Michel DeWilde
31 Jul 23
4
Damian Braga
31 Jul 23
4
Jeff Baxter
28 Jul 23
4
Joanne Cordeiro
28 Jul 23
4
Nell Beattie
28 Jul 23
4
VAUGHN B HIMES
28 Jul 23
4
Avi Mazaltov
28 Jul 23
4
Francisco Diaz-Mitoma
28 Jul 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
53.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 43 |
Opened positions | 4 |
Closed positions | 54 |
Increased positions | 1 |
Reduced positions | 37 |
13F shares | Current |
---|---|
Total value | 6.73 bn |
Total shares | 15.17 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Arch Venture Fund Vi | 13.03 mm | $15.96 mm |
Perceptive Advisors | 1.38 mm | $4.54 bn |
BLK Blackrock | 112.15 k | $368.96 mm |
Cambridge Investment Research Advisors | 100.37 k | $330.00 k |
Millennium Management | 89.21 k | $293.48 mm |
MS Morgan Stanley | 77.98 k | $256.55 mm |
Geode Capital Management | 67.19 k | $221.05 mm |
Vanguard | 62.63 k | $206.06 mm |
GAM General American Investors | 62.58 k | $205.90 mm |
Y-Intercept | 39.77 k | $130.85 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Jul 23 | Mazaltov Avi | Option (Right to Buy Common Shares) Common Shares | Grant | Acquire A | No | No | 1.3 | 52,500 | 68.25 k | 52,500 |
27 Jul 23 | Steven Gillis | Option (Right to Buy Common Shares) Common Shares | Grant | Acquire A | No | No | 1.3 | 52,500 | 68.25 k | 52,500 |
27 Jul 23 | John Robert Dillman | Option (Right to Buy Common Shares) Common Shares | Grant | Acquire A | No | No | 1.3 | 52,500 | 68.25 k | 52,500 |
27 Jul 23 | Blaine H. McKee | Option (Right to Buy Common Shares) Common Shares | Grant | Acquire A | No | No | 1.3 | 35,000 | 45.50 k | 35,000 |
27 Jul 23 | Anderson David Evander | Option (Right to Buy Common Shares) Common Shares | Grant | Acquire A | No | No | 1.3 | 52,500 | 68.25 k | 52,500 |
News
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
11 Apr 24
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
9 Apr 24
Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
14 Feb 24
Why Robinhood Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
14 Feb 24
Brii Biosciences Agrees To Acquire VBI's IP Rights In BRII-179 (VBI-2601) And Plans To Initiate Technology Transfer To Expand Clinical And Commercial Supplies
14 Feb 24
Press releases
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
9 Apr 24
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
3 Apr 24
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
2 Apr 24
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
22 Mar 24